We invite you to learn from renowned pioneers in the field of immuno-oncology and to pivot in our network of open innovation and collaboration during our five year anniversary Pivot Oncology Conference. During their key-notes (inter)national speakers will focus on breakthroughs in precision medicine used for cancer treatment from both the scientific and business perspective. In the satellite sessions Pivot Park based companies will inform you on the latest developments and breakthroughs in their specific field of expertise.
And be part of the Pivot Oncology ConferenceRegister Now
NTRC has launched an expansion of its Oncolines™ cancer cell line panel, from 66 to 102 cell lines. Oncolines™ are proliferation assays on a panel of genetically well-characterized cancer cell lines from diverse tumour tissue…Read more
AstraZeneca and Acerta Pharma announce results from the Phase I/II ACE-CL-001 clinical trial of acalabrutinib. Early data demonstrate clinical activity of acalabrutinib in difficult to treat chronic lymphocytic leukaemia. Phase I/II trial findings add to growing…Read more
NTRC is a precision medicine company dedicated to the development of new anti-cancer drugs. NTRC facilitates the development of novel therapies by providing cancer cell line profiling services (Oncolines™, OncolinesProfiler™, and SynergyFinder™) and target residence…Read more
Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced that a key patent that encompasses the entire GlycoConnect™ process used to prepare glycan-conjugated ADCs has…Read more
Guest? Potential Partner? Questions? Get in touch.
Get daily news and updates about our Event. New speakers, announcements, industry articles.